Longevity Biosciences: Science, Economy & Regulations

Is the "peptide craze" just a shortcut to weight loss, or the beginning of a structural shift in how we rebuild the human body? Today, we map the leap from metabolic stabilizers to cognitive enhancers like Semax and Cerebrolysin, and reveal the hidden systems turning these molecules into a global economic powerhouse. Key Takeaways: The $21B Explosion: Why the biohacking market is growing at 15.4%...

In this episode of the Longevity Biosciences series, we move beyond the hype to examine the rigorous biology of the two most famous molecules in geroscience: Rapamycin and Metformin . While often discussed as tools to "hack" biological time, the data reveals a complex reality of systems-level tradeoffs, tissue-specific benefits, and the puzzling divergence between living longer and measuring "youn...

The Invisible Architecture of GLP-1 & Peptide Drugs explores the profound transformation of global healthcare as it pivots from reactive disease management to a proactive paradigm of healthspan optimization . This episode deconstructs the "peptide craze," framing GLP-1 receptor agonists not merely as biological breakthroughs, but as a “system output” generated by the collision of regulatory pa...

From the $74 billion surge in sleep tourism to the medicalization of our grocery aisles and the rise of GLP-1 medications, we unpack how the search for restorative rest and longevity is reshaping global commerce. We also look inside the corporate world, where workplace wellness is shifting away from "perks" toward a strategic focus on combatting a global burnout crisis that costs companies $322 bi...